ClinicalTrials.gg
Not yet recruitingNCT07498647BR2251-201Updated Mar 27, 2026

Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia

A Phase 2 interventional study of BR2251 and Febuxostat in Gout and Hyperuricemia, sponsored by BioRay Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by BioRay Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is a randomized, double-blind, non-befloxacin-controlled, multicenter, phase II clinical trial, evaluating the efficacy, safety, and pharmacokinetic characteristics of BR2251 tablets when administered multiple times in subjects with primary gout and hyperuricemia.

This study is a dose exploration study, including a screening period (up to 2 weeks), a double-blind treatment period (12 weeks), and a follow-up period (2 weeks). The screened subjects were stratified based on whether their serum uric acid (sUA) was less than 480 μmol/L or greater than or equal to 480 μmol/L. They were randomly assigned to 4 treatment groups in a 1:1:1:1 ratio: the test drug group 1 (low-dose group), the test drug group 2 (medium-dose group), the test drug group 3 (high-dose group), and the control group (non-befloxacin tablets 40 mg), with 40 subjects in each group. Each group will use titration dosing.

02

Conditions studied

  • Gout and Hyperuricemia

Browse trials for

03

In context

Gout

345 studies on the registry are indexed under Gout; 49 are open to participants now.

This study's planned enrollment of 160 is above the median of 83 across 286 interventional studies indexed under Gout.

Browse Gout studies →

Lead sponsor

BioRay Pharmaceutical Co., Ltd. is the lead sponsor of 17 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Only those subjects who meet all the following inclusion criteria are eligible to participate in this study:
  • Voluntary participation in this trial and signing of the form, and those who can complete the trial according to the protocol;
  • Age between 18 and 75 years old (inclusive of the boundary value, based on the date of signing the informed consent form), regardless of gender;
  • (BMI) ≥ 18 kg/m2 and ≤ 35 kg/m2;
  • Meeting the 2015 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) gout classification criteria, and serum uric acid (sUA) ≥ 420 μmol/L during the screening period;
  • Women of reproductive age with negative pregnancy test during the screening period and before the first administration of the drug (D1 [allowing a time window of -7 days]), and both female and male subjects of reproductive age must agree to voluntarily take effective measures from the date of signing the informed consent form until 3 months after the last administration of the drug

Exclusion criteria

Exclusion Criteria:

  • Those who are known or suspected to be allergic to the test drug or its components, or who have previously been intolerant to febuxostat or have .
  • Subjects with secondary gout accompanied by hyperuricemia caused by other diseases or medications.
  • Those who have had acute gout attacks within the previous 2 weeks.
  • Those who have been diagnosed with uric acid nephropathy in the past or have imaging or clinical manifestations of urinary system stones (such as hematuria, back pain) within the previous 2 weeks.
  • Those with other joint lesions that the investigator considers may confuse gouty arthritis, such as rheumatoid arthritis, pyogenic arthritis, traumatic arthritis, psoriatic arthritis, pseudogout, systemic lupus erythematosus, or joint lesions caused by chemotherapy, radiotherapy, chronic lead poisoning, acute obstructive nephropathy, etc.
  • Those with any disease or surgical history that the investigator judges may affect the PK characteristics of the drug, such as peptic ulcer, irritable bowel syndrome, inflammatory bowel disease, digestive organ resection, kidney resection, etc.
  • Those who have used any organic anion transporter 1 and 3 (OAT1\&3) substrate drugs within the previous 2 weeks.
  • Those who have used any other uric acid-lowering drugs within the previous 2 weeks and have other concomitant medications that affect uric acid levels (including but not limited to losartan, calcium channel blockers, fenofibrate, atorvastatin calcium, alpha-glucosidase inhibitor, insulin sensitizers, DPP4 inhibitors, sodium-glucose cotransporter 2 (SGLT2) inhibitors, metformin) using a stable dose.
  • Those who have used aspirin within the previous 2 weeks.
  • Those who have used any diuretic within the previous 2 weeks.
  • Those with diseases that require long-term use of drugs metabolized by xanthine oxidase, including but not limited to azathioprine, mercaptopurine, etc.
  • Any abnormal laboratory test results at screening: a. Abnormal liver function, defined as or ALT values > 2× the (ULN), or > 1.5× ULN; b. WBC \< 3.0×109/L, \< 75×109/L, or HB \< 90 g/L; c. Scr > 1.5× ULN, or estimated \< 60 mL/min/1.73 m2 using the CKD-EPI formula; d. CK > 1.5× ULN.
  • Viral test results at screening: a. Those with positive surface antigen (HBsAg) and HBV-DNA > 1000 IU/mL; b. Those with positive antibody and positive HCV-RNA; d. Those with positive serum reaction; e. Those with positive syphilis antibody and requiring treatment after consultation with the infectious disease department.
  • Other serious diseases that may limit the participation of the subjects in this trial, such as: uncontrolled diabetes ( > 8.4% as assessed by the investigator); severe heart failure ( class II or above); acute coronary syndrome, acute cerebrovascular accident within the past 6 months; coronary revascularization such as stent implantation, coronary artery bypass surgery, and other heart and large vessel-related surgeries within the past 6 months; severe arrhythmia within the past 6 months including frequent premature ventricular contractions, ventricular tachycardia, atrial fibrillation/atrial flutter, severe bradycardia; uncontrolled hypertension (greater than 160/100 mmHg); severe respiratory diseases (such as obstructive pulmonary disease and history of bronchospasm) etc.
  • at screening showing prolonged interval (Fridericia formula) (males > 450 ms, females > 470 ms).
  • Those who have had or currently have malignant tumors within the past 5 years (excluding skin squamous cell carcinoma, basal cell carcinoma, and cervical carcinoma in situ that have been successfully treated and without recurrence evidence).
  • Had any active infection at the time of screening, or had a severe infection within 4 weeks before randomization (requiring intravenous antimicrobial treatment or hospitalization), or had any infection that required oral antibiotic treatment within 2 weeks before randomization.
  • Have undergone organ/tissue transplantation or stem cell transplantation.
  • Within 12 weeks before randomization or within the planned period of any major surgical operation.
  • Judged by the investigator, had a history of prescription drug abuse or use of prohibited drugs within 6 months before randomization.
  • Judged by the investigator, had a daily alcohol consumption of more than 14 units of alcohol (1 unit of alcohol = 360 mL of beer or 45 mL of alcohol with 40% content of spirits or 150 mL of wine) within 1 month before randomization.
  • Pregnant or lactating women.
  • Have participated in other drug clinical studies, and the time since the last medication is less than 30 days before screening or 5 half-lives of the original test drug (whichever is longer), or plan to participate in another drug clinical trial during the study period.
  • Those considered by the investigator to have other symptoms or conditions that are not suitable for participating in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    BR2251 low dose

    BR2251 (Experimental drug) low dose

    Drug: BR2251

  • Experimental
    BR2251 mid dose

    BR2251 (Experimental drug) mid dose

    Drug: BR2251

  • Experimental
    BR2251 high dose

    BR2251 (Experimental drug) high dose

    Drug: BR2251

  • Active comparator
    Febuxostat

    Febuxostat(40mg)

    Drug: Febuxostat

Interventions

  • DrugBR2251

    BR2251 low dose, mid dose, high dose, Titration regimen and Take orally once a day

  • Febuxostat(40mg) Titration regimen and Take orally once a day

06

What researchers measure

Primary outcomes

  1. Uric acid

    serum uric acid levels at various time points

    Time frame: Treated to 12 weeks

Secondary outcomes

  1. Uric acid

    serum uric acid levels meet the standard

    Time frame: Treated to 12 weeks

  2. Uric acid

    serum uric acid levels at various time points

    Time frame: at the 2nd, 4th, 6th, 8th and 10th weeks of treatment

  3. The proportion and frequency of patients with acute gout who require treatment

    The proportion and frequency of patients experiencing gout attacks during the 12-week treatment period

    Time frame: 12-week treatment period

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Oct 2026, 6 months later.

Of 25 industry-sponsored phase 2 interventional studies under Gout, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 19. This study's planned 6 months is below that.

Counting every sponsor, half of 30 studies reached it within 14 months; a quarter within 7 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Mar 27, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Nov 30, 2026
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07498647
Lead sponsor
BioRay Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 27, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Oct 1, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Mar 27, 2026

Study contacts

Xiaofeng Zeng, Doctor
Contact
xiaofeng.zeng@cstar.org.cn
+8613501069845

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion